Cancer-related fatigue and associated disability in post-treatment cancer survivors

the ONA take:

Cancer-related fatigue (CRF) is the most common symptom for patients with cancer. However, data on its prevalence in the posttreatment period is limited.

Using a self-administered mail-based questionnaire, these researchers sought to measure occurrence of CRF in three cohorts (16 to 18 months posttreatment, 2 to 3 years posttreatment, and 5 to 6 years posttreatment) of disease-free survivors of breast, prostate, or colorectal cancer.

The study generated a 63% response rate (2,294 questionnaire packages were returned). Twenty-nine percent of respondents reported significant fatigue, although fatigue levels did not differ between time cohorts.

Reports of fatigue were significantly higher in survivors of breast or colorectal cancer compared with survivors of prostate cancer.

The researchers conclude that approximately one-third of cancer survivors experience fatigue for up to 6 years after treatment. Clinicians should be aware that fatigue can be a chronic condition, and should routinely assess for it.

fatigue-wake-up-call-article
Cancer-related fatigue is the most common symptom for patients with cancer.
Cancer-related fatigue (CRF) is the most prevalent and distressing symptom among cancer patients and survivors. However, research on its prevalence and related disability in the post-treatment survivorship period remains limited.
READ FULL ARTICLE From Springer
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs